#AVIR

Lead report

Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch (NASDAQ:AVIR)

Atea Pharma (AVIR) Q2 2026 earnings call: Phase III C-BEYOND HCV win vs Epclusa, C-FORWARD catalyst Q1’27, cash runway—read now.